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http://dx.doi.org/10.1016/j.ahj.2016.05.007Atrial fibrillation (AF) predisposes patients to the
development of atrial thrombi, most often in the left
atrial (LA) appendage (LAA). Left atrial appendage
thrombi are the dominant source of embolism (N90%)
in patients with nonvalvular AF,1,2 and LA/LAA thrombi
are identified in ~10% of patients with AF.3
The use of a transesophageal echocardiogram (TEE) is
an established standard for detecting the presence of LA/
LAA thrombi.4–6 If an LA/LAA thrombus is detected on a
TEE, current guidelines1,7 recommend vitamin K antag-
onist (VKA) treatment with a therapeutic international
normalized ratio (INR) of 2.0 to 3.0 for at least 3 weeks
and a follow-up TEE to ensure thrombus resolution prior
to interventions such as cardioversion. However, report-
ed thrombus resolution rates with VKAs vary between
Lip et al 127
American Heart Journal
Volume 178approximately 50% and 90% after a median of 4 weeks’
treatment.8–13 Reasons for this wide range of resolution
rates include differences in patient populations (eg, with
or without the inclusion of valvular AF14; first diagnosed
or persistent AF) and anticoagulation strategies/treatment
durations, or the use of imaging strategies evaluated in
relatively small observational studies.8–11,15,16 Data on
LA/LAA thrombus resolution after non-VKA oral anti-
coagulant (NOAC)17 treatment are scarce and largely
comprise case reports, which generally indicate favorable
outcomes.18–22
The primary objective of the prospective X-TRA study
was to explore the use of the NOAC rivaroxaban for the
resolution of LA/LAA thrombi in patients with nonvalv-
ular AF or atrial flutter who had a TEE-confirmed LA/LAA
thrombus. The objective of the CLOT-AF registry was to
provide retrospective thrombus-related patient outcome
data after standard-of-care anticoagulant treatment in
patients with nonvalvular AF or atrial flutter who had
TEE-documented LA/LAA thrombi.
Methods
Study design and patient population
X-TRA study. In brief, the X-TRA study (ClinicalTrials.
gov identifier NCT01839357) was a prospective, inter-
ventional, single-arm, open-label, multicenter study, as
described previously.23 X-TRA was designed to explore
once-daily (od) rivaroxaban (20 mg od, or 15 mg od in
patients with creatinine clearance 15-49 mL/min) for the
resolution of LA/LAA thrombi in patients with nonvalv-
ular AF or atrial flutter and LA/LAA thrombus confirmed
using a TEE at baseline. Eligible patients had to be VKA/
NOAC naïve or untreated within 1 month prior to signing
the informed consent form (treatment of up to 72 hours
with VKA, heparin, or a low-molecular-weight heparin
was allowed before the start of rivaroxaban), or,
following an amendment, VKA pretreated but with
suboptimal or ineffective INR levels (ie, b2.0, document-
ed with at least 2 consecutive measurements that were at
least 24 hours apart) within the last 6 weeks. The primary
end point was the complete LA/LAA thrombus resolution
rate on the centrally adjudicated end-of-treatment (EOT)
TEE after 6 weeks’ treatment with rivaroxaban. The
secondary objectives were centrally adjudicated catego-
ries of thrombus outcome (resolved, reduced, un-
changed, larger, or new) confirmed on TEE at EOT,
incidence of the composite of stroke and noncentral
nervous system systemic embolism at EOT and during
follow-up, and incidence of all bleeding events (major
bleeding according to International Society on Thrombo-
sis and Haemostasis criteria24 and nonmajor bleeding) at
EOT and during follow-up.
CLOT-AF registry. In brief, the CLOT-AF registry
(ClinicalTrials.gov identifier NCT01928979) retrospec-
tively collected thrombus-related patient outcome dataafter standard-of-care anticoagulant treatment in patients
with nonvalvular AF or atrial flutter who had LA/LAA
thrombi on a TEE recorded in their medical file.23
The primary outcome of interest was the reported
thrombus resolution rate confirmed on a TEE after 3 to
12 weeks of anticoagulation therapy based on the routine
practice of the participating centers without central
adjudication. Secondary end points were rates of stroke
or noncentral nervous system systemic thromboembo-
lism and all bleeding events (major [International Society
on Thrombosis and Haemostasis criteria],24 nonmajor,
unknown severity).
Thrombus assessment
X-TRA study. To ensure an objective assessment, TEE
images were assessed centrally by independent adjudica-
tors in a blinded fashion without knowledge of whether
an image was pretreatment or posttreatment. The
adjudicators were specialists in cardiology with a specific
interest in TEE who were not otherwise involved in
the study.
Each TEE was reviewed by 2 adjudicators. Both had to
agree in their assessment, that is, absence of a thrombus
or degree of thrombus burden. A third adjudicator
performed the final judgment if their assessment differed
by N1 mm for thrombi with an average thrombus
diameter ≤10 mm, by N2 mm for thrombi with an
average diameter N10 to ≤20 mm, or by N3 mm for
thrombi with an average diameter N20 mm.
Predefined thrombus outcome criteria were as follows:
“resolved” if no thrombus was detectable on the EOT TEE
and “reduced”/“larger” if the thrombus was smaller/
larger than at baseline (dependent on thrombus size). To
qualify as a reduction or an increase compared with
baseline, the thrombus size had to be reduced/enlarged
by N1 mm for thrombi b10 mm in diameter at baseline, by
N2 mm for thrombi of 10 to ≤20 mm in diameter at
baseline, and by N3 mm for thrombi N20 mm in diameter
at baseline. If the change was b1 mm, the thrombus
outcome was assessed as “unchanged.” A “new” throm-
bus was one that had not been present on the baseline
TEE. Patients were categorized according to the most
severe category into which any thrombus fell.
CLOT-AF registry. The image assessment was used as
recorded in the patients' medical file without adjudica-
tion, in contrast to X-TRA.
Ethical considerations
For both studies, approval from the appropriate
independent ethics committee/institutional review
board was obtained for all participating centers before
the start of the study, in accordance with the ethical
principles of the Declaration of Helsinki, Good Clinical
Practice and local laws, regulations, and organizations, as
applicable. Informed consent was obtained from all
patients; for the CLOT-AF registry, informed consent
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local regulations.
Statistical evaluation
In both studies, statistical analyses were of an
explorative and descriptive nature. Mean values were
calculated based on the number of available data.
Frequency distributions include a category for missing
data, if applicable. The studies did not aim to confirm or
refute any predefined hypotheses. Statistical evaluations
were performed using the software package SAS release
9.4 (SAS Institute Inc, Cary, NC).
X-TRA study. The sample size was estimated based on
the expected presence of LA/LAA thrombi detected on a
TEE in the participating study sites and aimed to enroll
60 patients. Enrolled patients were analyzed on an
intention-to-treat (ITT) basis. Patients with complete
data on baseline and EOT TEEs were included in the
modified ITT (mITT) population. The primary analysis
evaluated the thrombus outcome in the mITT population.
Exact (Clopper-Pearson) 95% CIs for the probability of
complete thrombus resolution in the LA/LAA were
calculated. As a sensitivity analysis (worst-case scenario
applied), thrombus resolution was calculated based on
the ITT population, considering patients without an
evaluable EOT TEE as still having a thrombus. In addition,
exact (Clopper-Pearson) 95% CIs were calculated for the
combined category of resolved/reduced.
CLOT-AF registry. No sample size was calculated, but
at the planned 15 to 20 study sites, the inclusion of
~150 patients was expected. The ITT population was the
number of eligible and enrolled patients, and the mITT
population was the number of patients with baseline and
EOT TEEs. The primary analysis evaluated the thrombus
resolution rate using exact (Clopper-Pearson) 95% CIs in
the mITT patient population.
As best-/worst-case analyses, thrombus resolution was
calculated based on the ITT population, considering
patients without an evaluable EOT TEE as having resolved
thrombus/still having a thrombus.
The studies were funded by Bayer Pharma AG. The
authors are responsible for the design and conduct of the
studies and all study analyses, the drafting of the
manuscript, and its final contents.
Results
Disposition of patients, demographics, and baseline
characteristics
X-TRA study. The X-TRA study was conducted at
17 study centers in 7 countries between August 2013 and
December 2014. A total of 60 patients were included in
the ITT population. The mITT population with complete
TEE data encompassed 53 patients: 7 patients were
excluded from the mITT population, of these, 4 patients
had no thrombus at baseline TEE as adjudicated (1 patientwithdrew from the study because of an adverse event),
and 3 patients had no EOT TEE (1 patient died of acute
heart failure, 1 patient emigrated to another country
because of a war, and 1 patient was hospitalized for heart
transplantation). The patient disposition is summarized in
Figure. No patients were lost to follow-up.
Almost all patients (95.0%) were from Eastern European
countries, half were male, and mean patient age was
70 years, with most patients (61.7%) being 65 years or
older. Mean body weight was 85 kg, and 48.3% of patients
had a body mass index of ≥30 kg/m2.
Approximately three-quarters of patients (76.6%) pre-
sented with persistent, long-standing persistent, or
permanent AF. The median CHADS2 and CHA2DS2-VASc
scores were 2 and 4, respectively; most patients were in
the high-risk category—66.7% of patients had a CHADS2
score of ≥2.0 and 83.3% had a CHA2DS2-VASc score of
≥2.0. The most common risk factors were hypertension
(81.7%), heart failure (55.0%), prior stroke/transient
ischemic attack (18.3%), and diabetes (15.0%). Approx-
imately three-quarters of the patients (76.7%) had no
prior VKA or NOAC treatment (Table I, ITT). These
patients were VKA/NOAC naïve or untreated according
to the original study design before the last amendment of
the protocol. Results of the TEE analysis are summarized
in online Supplementary Table I. According to the central
TEE assessment, a total of 55 LAA thrombi (mean values ±
SD: diameter 15 ± 7.5 mm, area 130.8 ± 108.6 mm2) and
3 LA thrombi (mean values ± SD: diameter 18.7 ± 3.8 mm,
area 162.7 ± 72.6 mm2) were detected on TEE in
53 patients (mITT population), in which 5 patients had
2 thrombi (all in the LAA except for 1 LA thrombus).
CLOT-AF registry. Medical records at the study sites
encompassed the period from January 2010 to February
2013. Only the extension of the originally planned
screening period from January 2011 to January 2010
allowed us to meet the target number of ~150 patients.
The retrospective CLOT-AF registry included 156 patients
in the ITT population at 23 centers of the same 7 countries
as in X-TRA. The mITT population with complete TEE
data encompassed 96 patients (Figure).
In contrast to the X-TRA study, patient numbers were
balanced between Eastern (52.6%) and Western (47.4%)
European countries. In total, 66.0% of the patients were
male, and mean patient age was 68 years; 62.0% were
65 years or older. Mean body weight was 82 kg, and
25.0% of patients had a body mass index of ≥30 kg/m2.
The number of patients with persistent, long-standing
persistent, or permanent AF was 56.4%; information on
the type of AF was missing for 22.4% of patients. The
median CHADS2 and CHA2DS2-VASc scores were 2.0 and
3.0, respectively. The most common risk factors were
hypertension (81.4%), heart failure (48.1%), diabetes
(22.4%), and myocardial infarction (16.7%); prior
stroke/transient ischemic attack was recorded in 10.3%
of patients (Table I, ITT).
Figure
Disposition of patients. *One withdrew due to gastrointestinal bleeding and hepatic metastasis after 7 days of treatment, and had no baseline
thrombus as adjudicated. †Female, 57 years old, died of acute left ventricular failure, unrelated to study treatment. ‡In this retrospective study, this
information was missing. §Female, 83 years old, died of cardiac decompensation and cardiac arrest 13 days after the baseline TEE.
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patients were VKA naïve. Owing to the retrospective
nature of this registry, only limited information on prior
VKA use and INR monitoring was available.
Treatment in X-TRA and observation in CLOT-AF
X-TRA study. Most (81.7%) of the ITT patients
received oral rivaroxaban 20 mg od; 18.3% with
moderate-to-severe renal impairment received the lower
dose of 15 mg od. Mean compliance calculated by tablet
accountability was almost 100%. The mean treatment
duration was 46 days (ITT, mITT). Most patients had their
EOT TEE performed within the recommended time
frame, after 6 to 8 weeks of rivaroxaban treatment
(85.0% ITT, 90.6% mITT).
CLOT-AF registry.A total of 148 (94.9%) of 156 patients
had a record of any anticoagulation treatment. In most
patients, the anticoagulant treatment was a VKA (127/156
patients; 81.4%), either prescribed alone or in combination
with another treatment (most often low molecular weight
heparin or unfractionated heparin). For those treated
with a VKA, the types of VKA used included acenocou-
marol in 45 patients (28.8%), warfarin in 29 patients
(18.6%), phenprocoumon in 27 patients (17.3%),fluindione in 25 patients (16.0%), and 1 patient with
dicoumarol (0.6%).
The observation period started with the diagnosis of an
LA/LAA thrombus on the baseline TEE. In the mITT
population, 83.3% of patients had the protocol-defined
observation period of 3 to 12 weeks; for 5 patients (5.2%),
this period was b3 weeks or unknown, and for 11 patients
(11.5%), it was N12 weeks (up to 6 months).
Thrombus resolution rates
X-TRA study. In the X-TRA study, the thrombus
resolution rate was 41.5% by patient (22/53 mITT
patients, 95% CI 28.1%-55.9%) based on central TEE
assessments (Table II). Resolved or reduced thrombus
was evident in 60.4% (32/53 mITT patients, 95% CI
46.0%-73.6%) of patients (Table II). Thrombus resolution
rates in subgroups are presented in online Supplementary
Table II. Patients with thrombus resolution tended
to have lower thromboembolic risk scores (CHADS2/
CHA2DS2-VASc) and to be older (aged N75 years).
The resolution rate by individual thrombus outcome
was 46.6% (27/58, mITT). With regard to the 5 patients
with 2 thrombi each at baseline, at EOT 2 patients had
both their LAA thrombi resolved, 2 patients had 1 LAA
Table I. Demographic data and baseline characteristics of subjects enrolled in the X-TRA study and the CLOT-AF registry (ITT population)
Prospective X-TRA study (n = 60) Retrospective CLOT-AF registry (n = 156)
Region, n (%)
Eastern Europe 57 (95.0) 82 (52.6)
Western Europe 3 (5.0) 74 (47.4)
Sex: male, n (%) 30 (50.0) 103 (66.0)
Age (y), mean ± SD 69.6 ± 11.0 67.7 ± 9.6
Age category (y), n (%)
b65 23 (38.3) 59 (37.8)
65-74 13 (21.7) 57 (36.5)
≥75 24 (40.0) 40 (25.6)
Body weight (kg), mean ± SD 85.1 ± 17.6 81.7 ± 15.5
BMI (kg/m2), mean ± SD 30.7 ± 6.0 27.8 ± 4.9
BMI (kg/m2), n (%)
b25 8 (13.3) 32 (20.5)
25-b30 23 (38.3) 56 (35.9)
≥30 29 (48.3) 39 (25.0)
Missing – 29 (18.6)
CrCl (mL/min), n (%)⁎
30-b50 11 (18.3) 15 (9.6)
≥50 49 (81.7) 96 (61.5)
Not recorded – 45 (28.8)
Medical history, n (%)
Presence of any risk factor 56 (93.3) 144 (92.3)
Arterial hypertension 49 (81.7) 127 (81.4)
Congestive heart failure/left ventricular failure 33 (55.0) 75 (48.1)
Diabetes mellitus 9 (15.0) 35 (22.4)
Myocardial infarction 5 (8.3) 26 (16.7)
Stroke/transient ischemic attack 11 (18.3) 16 (10.3)
Peripheral artery disease 5 (8.3) 12 (7.7)
Thromboembolism/non-CNS systemic embolism 2 (3.3) 9 (5.8)
Complex aortic plaque 3 (5.0) 9 (5.8)
Referral diagnosis, n (%)
AF 57 (95.0) 151 (96.8)
First-diagnosed 4 (6.7) 13 (8.3)
Paroxysmal 2 (3.3) 19 (12.2)
Persistent/long-standing persistent 32 (53.3) 63 (40.4)
Permanent 14 (23.3) 25 (16.0)
Missing 5 (8.3) 35 (22.4)
Atrial flutter, alone† 3 (5.0) 5 (3.2)
CHADS2 score‡, median 2.0 2.0
CHADS2 category, n (%)
0 3 (5.0) 4 (2.6)
1 17 (28.3) 30 (19.2)
≥2 40 (66.7) 72 (46.2)
Missing – 50 (32.1)
CHA2DS2-VASc score‡; median 4.0 3.0
CHA2DS2-VASc category, n (%)
0 (or 1, if female only) 2 (3.3) 1 (0.6)
1 (except for female alone) 8 (13.3) 12 (7.7)
≥2 50 (83.3) 91 (58.3)
Missing – 52 (33.3)
No prior use of VKA§/NOAC, n (%) 46 (76.7) 87 (55.8)
Abbreviations: BMI, body mass index; CNS, central nervous system; CrCl, creatinine clearance.
⁎ In X-TRA, no patient with CrCl b15 mL/min was enrolled. In CLOT-AF, the CrCl categories were as follows: b50 mL/min, ≥50-80 mL/min, and N80 mL/min.
†Both AF and atrial flutter were recorded for 6 ITT patients in the X-TRA study and for 14 ITT patients in the CLOT-AF registry.
‡High number of missing records in case of CLOT-AF (see number missing in the presentation by category).
§ For CLOT-AF, numbers refer to “no prior use of VKA,” because in the participating countries, most NOACs were not available during the observation period.
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1 patient and LA in 1 patient), and 1 patient had 1
LAA thrombus resolved and 1 enlarged (maximum area
50-N51 mm2, maximum diameter 6-N10 mm). Of the2 patients with a single LA thrombus at baseline, in 1
patient the LA thrombus was resolved and in the other
there was no LA thrombus at EOT, but an LAA thrombus
appeared.
Table II. Resolution rates of LA/LAA thrombi
Evaluation set Total n
Thrombus resolution
95% CIn thrombus resolved %
Prospective X-TRA study
Complete thrombus resolution (assessed by blinded adjudicators)⁎ mITT 53 22 41.5 28.1-55.9
Complete thrombus resolution (assessed by blinded adjudicators), worst-case
scenario considering subjects without EOT TEE as nonresolved
ITT 60 22 36.7 24.6-50.1
Resolved or reduced thrombus (assessed by blinded adjudicators)† mITT 53 32 60.4 46.0-73.6
Retrospective CLOT-AF registry
Complete thrombus resolution mITT 96 60 62.5 52.0-72.2
Complete thrombus resolution by region
Eastern Europe mITT 46 26 56.5 41.1-71.1
Western Europe mITT 50 34 68.0 53.3-80.5
Complete thrombus resolution, worst-case scenario considering subjects
without EOT TEE as nonresolved
ITT 156 60 38.5 30.8-46.6
Complete thrombus resolution, best-case scenario considering subjects
without EOT TEE as resolved
ITT 156 120 76.9 69.5-83.3
⁎ This includes 2 patients who had 2 thrombi each. Both thrombi were resolved in each case.
† In 12 patients (22.6%), thrombi were larger, and in another 9 patients (17.0%), thrombi were found unchanged (blinded central assessment); no patients had a new thrombus.
Lip et al 131
American Heart Journal
Volume 178CLOT-AF registry. In the CLOT-AF registry, the
recorded thrombus resolution rate was 62.5%
(60/96 mITT patients, 95% CI 52.0%-72.2%) (Table II).
The thrombus resolution rate was better in patients from
Western European countries (68.0%; 34/50 patients) than
from Eastern European countries (56.5%; 26/46 patients)
(Table II). The thrombus resolution rate for the 80
patients who had both TEEs performed within the range
of 3 to 12 weeks was 61.2% (95% CI 50.0%-71.9%), that is,
similar to the 62.5% reported for the 96 patients who had
2 TEEs.
Secondary outcome measures
X-TRA study. There were no reports of stroke or
noncentral nervous system systemic embolism during
the treatment period and the 30-day follow-up. In
addition, no patients experienced a major bleeding
event. Nonmajor bleeding events were recorded in
5 patients (Table III).
All patients took at least one tablet of study medication.
Treatment-emergent adverse events (TEAEs) occurred in
36.7% of patients. Treatment-emergent adverse events
reported in more than a single patient were bradycardia,
cardiac failure, hyperthyroidism, nausea, peripheral
edema, thyroid neoplasm, headache, and chronic renal
failure. Overall, 3 patients experienced TEAEs that were
assessed by the investigator as related to the study drug
(ear hemorrhage, gingival bleeding, and petechia). The
drug-related treatment-emergent serious adverse event
rate was 1.7%.
CLOT-AF registry. Stroke/noncentral nervous system
systemic embolism after baseline TEE or with unknownstart date was recorded for 4 of the 156 patients. A major
bleeding event was recorded for 1 patient who had
spontaneous nonhemorrhoidal bleeding in the gastro-
intestinal tract (with INR b2.0) (Table III).Discussion
Current guidelines recommend VKA therapy for
3 weeks upon detection of an LA/LAA thrombus in
patients with AF and long-term treatment for those with a
residual thrombus,1 but existing clinical evidence support-
ing the use of NOACs for LA/LAA thrombus resolution is
limited to isolated case reports or small case series (usually
from single-center studies).23 The X-TRA study is the first
prospective, multicenter, interventional study examining
thrombus resolution with a NOAC (rivaroxaban) in
VKA-naïve patients or patients receiving suboptimal or
ineffective VKA therapy (INR b2.0). The results showed
that resolved or reduced thrombus (as assessed centrally by
blinded, independent adjudicators)was evident in 60.4% of
the mITT patient population including 2 patients with 2
thrombi resolved in each case, demonstrating the potential
of rivaroxaban in this setting.
In X-TRA, patients were predominantly from Eastern
European countries; approximately three-quarters were
treatment naïve or untreated, and most had persistent or
permanent AF. This particularly reflects the gap between
guideline recommendation and local practice in reality,
which means those patients with diagnosed AF were not
adequately treated with an oral anticoagulant as recom-
mended. Owing to the limitations of TEE and other
imaging modalities, it could not be confirmed whether
Table III. Stroke, non-CNS systemic embolism, bleeding, and
AE rate (ITT population)
Other outcomes Total n n with event %
Prospective X-TRA study
Stroke/non-CNS systemic embolism 60 0 0
Bleeding events
Major bleeding 60 0 0
Nonmajor bleeding 60 5 8.3
TEAEs 60 22 36.7
Related TEAE 60 3 5.0
TEAE causing premature study termination 60 3 5.0
TEAE of special interest⁎ 60 4 6.7
Treatment-emergent serious AE 60 7 11.7
Related treatment-emergent serious AE 60 1 1.7
Death 60 1 1.7
Retrospective CLOT-AF registry
Stroke/transient ischemic attack or
non-CNS systemic embolism†,‡
156 4 2.6
(Major) bleeding events 156 1 0.6
Abbreviations: AE, adverse event; CNS, central nervous system.
⁎ Events of special interest were all occult and overt bleeding events considered by the
investigator to be serious; thrombocytopenia, including decreased platelet count;
hypersensitivity reactions; severe skin reactions; and severe liver injury.
† Three patients had a record of stroke/transient ischemic attack and 1 patient a
record of a non-CNS systemic embolism. Available patient information indicates that
the events had occurred shortly after the baseline TEE (1 patient), or that the exact
date of the event was unknown (3 patients).
‡Of the 96 patients in the mITT population, 2 patients (2.1%) had a record of stroke/
transient ischemic attack with an unknown start date and 1 patient (1.0%) had a
major bleeding event.
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or if they had an “old” thrombus at screening.
Based on the rate of resolved/reduced thrombi after
rivaroxaban treatment, and the fact that there were no
stroke or thromboembolic events during treatment and
follow-up and favorable safety data, rivaroxaban seems to
be a treatment option for patients with nonvalvular AF or
atrial flutter and an LA/LAA thrombus. Data from
prospective studies of the other NOACs in this setting
are currently lacking, although one prospective study
with dabigatran is ongoing.25 In this context, the X-TRA
study provides important insights into a challenging
clinical problem and the potential of NOACs for this
subgroup of AF patients.
It should be noted that in X-TRA, the duration of AF or
atrial flutter was not recorded. It might be the case that the
longer patients had AF for, the higher the possibility that
they had “old” LA/LAA thrombi (especially if that theywere
not treatedwith an oral anticoagulant as recommended). In
the X-TRA study, 76.6% of patients had persistent or
permanent AF and 76.7% had no prior use of an oral
anticoagulant. Therefore, some patients might have had
“old” LA/LAA thrombi instead of a newly formed thrombus.
These may be part of the reasons for the relatively lower
than expected resolution rate observed in X-TRA (eg,
N80%).23 However, in one prospective and serial study, the
LAA thrombus resolution rateswere16% at 1month, 42% at
3 months, and 56% at 12 months.26 This finding providesencouragement that residual thrombi might be resolved
with continuous long-term anticoagulation treatment,
which is in line with guideline recommendations.
Published data on LA/LAA thrombus resolution rates
after VKA therapy vary, and the reported resolution rate
in a prospective study was relatively low.26 To further
understand how patients with nonvalvular AF or atrial
flutter who had LA/LAA thrombi on a TEE were treated in
routine practice and their outcomes, the retrospective
CLOT-AF registry collected data between 2010 and 2013
from the same 7 countries as X-TRA to reflect
standard-of-care in those health care settings. The
reported thrombus resolution rates were also lower
than expected (eg, N80%) but still within the expected
range after VKA treatment; however, approximately
one-third of the data were missing in this retrospective
registry, which limits the generalization of the data.
Furthermore, a direct comparison of the results of
X-TRA and CLOT-AF cannot be made because of the
nature of the studies (prospective adjudicated study vs
retrospective nonadjudicated registry), differences in
patient demographics and disease severity, as well as
data quality (ie, centrally adjudicated data vs hospital
medical records). Thus, our results report descriptive
observations, and no causality is implied.
What is most important for the patients from a clinical
perspective? Ultimately it is about whether the patients
are safe frommajor clinical events. In the X-TRA study, no
stroke or peripheral embolism or major bleeding was
reported during the 6-week treatment period and the
30-day follow-up period. The overall reported rate for
TEAEs and bleeding events was in the expected range
observed in other phase III/IV studies of rivaroxaban27,28
and the drug-related treatment-emergent serious adverse
event rate was also low (1.7%). Thus, no safety concerns
were raised in X-TRA.
In conclusion, the X-TRA study showed that resolved or
reduced thrombus after rivaroxaban treatment was
evident and consistent with LA/LAA thrombus resolution
with VKA therapy from prior retrospective observational
case series and the retrospective CLOT-AF registry. The
results suggest that rivaroxaban seems to be a potential
option for the treatment of TEE-detected LA/LAA thrombi
in patients with AF or atrial flutter.Acknowledgments
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